company background image
TSHA logo

Taysha Gene Therapies NasdaqGS:TSHA Stock Report

Last Price

US$2.14

Market Cap

US$431.0m

7D

-12.3%

1Y

219.5%

Updated

22 Jul, 2024

Data

Company Financials +

Taysha Gene Therapies, Inc.

NasdaqGS:TSHA Stock Report

Market Cap: US$431.0m

TSHA Stock Overview

A gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.

TSHA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Taysha Gene Therapies, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Taysha Gene Therapies
Historical stock prices
Current Share PriceUS$2.14
52 Week HighUS$4.32
52 Week LowUS$0.62
Beta0.39
11 Month Change-27.70%
3 Month Change-15.42%
1 Year Change219.50%
33 Year Change-88.08%
5 Year Changen/a
Change since IPO-91.11%

Recent News & Updates

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Recent updates

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 20

Taysha: Produces Solid Data But Has Abandoned Programs

Feb 06

Taysha Gene Therapies Gets A 'Thumbs Up'

Mar 07

Shareholder Returns

TSHAUS BiotechsUS Market
7D-12.3%0.2%-2.1%
1Y219.5%12.5%19.0%

Return vs Industry: TSHA exceeded the US Biotechs industry which returned 12.5% over the past year.

Return vs Market: TSHA exceeded the US Market which returned 19% over the past year.

Price Volatility

Is TSHA's price volatile compared to industry and market?
TSHA volatility
TSHA Average Weekly Movement15.3%
Biotechs Industry Average Movement10.6%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: TSHA's share price has been volatile over the past 3 months.

Volatility Over Time: TSHA's weekly volatility has decreased from 31% to 15% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201952Sean Nolanwww.tayshagtx.com

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center.

Taysha Gene Therapies, Inc. Fundamentals Summary

How do Taysha Gene Therapies's earnings and revenue compare to its market cap?
TSHA fundamental statistics
Market capUS$430.95m
Earnings (TTM)-US$118.00m
Revenue (TTM)US$14.16m

30.4x

P/S Ratio

-3.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TSHA income statement (TTM)
RevenueUS$14.16m
Cost of RevenueUS$0
Gross ProfitUS$14.16m
Other ExpensesUS$132.16m
Earnings-US$118.00m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.59
Gross Margin100.00%
Net Profit Margin-833.60%
Debt/Equity Ratio75.2%

How did TSHA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.